300 NORTH CAPITAL, LLC - INTERCEPT PHARMACEUTICALS IN ownership

Back to all holdings Add to watchlist

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 195 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.

Links
Filings
External links
Quarter-by-quarter ownership
300 NORTH CAPITAL, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2015$736,000
+81.7%
2,609
+0.5%
0.16%
+74.2%
Q4 2014$405,000
-33.8%
2,595
+0.3%
0.09%
-42.6%
Q3 2014$612,0000.0%2,5880.0%0.16%
+7.3%
Q2 2014$612,000
-28.3%
2,5880.0%0.15%
-31.7%
Q1 2014$854,000–2,588–0.22%–
 Download
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2015
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders